To the Editor

After the first reported case of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in Wuhan, China, in December 2019, the contagion has spread rapidly and has become a global pandemic \[[1](#tri13626-bib-0001){ref-type="ref"}\]. There are as of yet no published studies beyond the case series describing the incidence and clinical course of COVID‐19 in transplant recipients, a population potentially at high risk due to the ongoing immunosuppression and higher risk of comorbidities \[[2](#tri13626-bib-0002){ref-type="ref"}\]. This pandemic has had a major impact in transplant physicians and healthcare workers as well \[[3](#tri13626-bib-0003){ref-type="ref"}\], and this crisis has meant reducing or even interrupting transplant program activity, with a subsequent impact on patient morbidity and mortality that is still hard to quantify.

In contrast with the current bleak situation at our hospitals, these challenging times have unequivocally shown how lively and collaborative the medical community is. Healthcare professionals and scientists across the globe have rapidly shared the results of their studies, leading to a prompt identification of the virus, the development of assays for patient screening, and the initial definition of its pathogenic mechanisms. Over the last few months, we have witnessed an unprecedented proliferation of clinical trials designed to test the efficacy of different molecules in preventing viral replication and restraining the uncontrolled inflammatory response associated with COVID‐19 (Table [1](#tri13626-tbl-0001){ref-type="table"}). Importantly, these clinical studies are directly testing in humans the hypotheses generated using *in vitro* and *in vivo* animal models in a truly translational endeavor. Despite the sometimes unsuccessful efforts to treat this infection and the unavoidable lag required to generate an effective vaccine, this experience testifies to the critical role that basic, mechanistic studies play in improving human health.

###### 

Main treatments currently being tested on COVID‐19 patients.

  Drug                                         Mechanism of action                                                                                                                                   Registered trials (*n*)   Rationale\*
  -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------------------------------------------------------------------------------------
  **Antivirals and antimalarials**                                                                                                                                                                                             
  Arbidol                                      Inhibitor of virus‐mediated fusion with target membrane                                                                                               9                         *In vitro* data
  Bromhexine hydrochloride                     Transmembrane protease serine inhibitor                                                                                                               2                         *In vitro* data
  Camostat mesilate                            TMPRSS2 inhibitor                                                                                                                                     3                         Animal models of SARS‐CoV
  Chloroquine                                  Increases endosomal pH                                                                                                                                46                        *In vitro* data
  Danoprevir                                   HCV NS3 protease inhibitor                                                                                                                            1                         FDA approved for HCV infection
  Darunavir                                    Protease inhibitor                                                                                                                                    2                         *In vitro* data
  Favipiravir                                  RNA‐dependent RNA polymerase inhibitor                                                                                                                9                         Animal models of Zaire Ebola virus
  Hydroxychloroquine                           Increases endosomal pH                                                                                                                                109                       *In vitro* data
  Hydroxychloroquine + azithromycin            Increases endosomal pH                                                                                                                                29                        *In vitro* data; Single‐arm trial showed reduction of viral load at day 6 postinclusion.
  Interferon, interferon α2β, interferon α1β   Initiate JAK‐STAT signaling cascades                                                                                                                  27                        *In vitro* data
  Lopinavir/ritonavir                          Protease inhibitor                                                                                                                                    31                        *In vitro* and animal models of MERS‐CoV; RCT trial with negative results in severe COVID‐19
  Nitric oxide gas                             Inhibits viral protein and RNA synthesis                                                                                                              8                         *In vitro* model of SARS‐CoV
  Oseltamivir                                  Viral neuraminidase inhibitor                                                                                                                         10                        FDA approved for influenza A and B infection
  Remdesivir                                   Nucleoside analog inhibitors                                                                                                                          9                         *In vitro* and animal models of SARS‐CoV and MERS‐CoV
  **Anti‐inflammatories**                                                                                                                                                                                                      
  Baricitinib                                  JAK/STAT inhibitor                                                                                                                                    5                         *In vitro* data
  Bevacizumab                                  Monoclonal antibody against VEGF                                                                                                                      3                         Increased VEGF in blood of patients
  Clazakizumab                                 Humanized monoclonal anti‐IL‐6 antibody                                                                                                               3                         Humanized monoclonal anti‐IL‐6 antibody
  Colchicine                                   Inhibition of the assembly of the NLRP3 inflammasome                                                                                                  5                         Animal models of influenza virus infection
  Convalescent plasma                          Plasma with specific antibody                                                                                                                         28                        Studied in outbreaks of H1N1 influenza virus SARS‐CoV‐1, MERS‐CoV
  Eculizumab                                   Humanized anti‐C5 monoclonal Ab                                                                                                                       2                         Complement activation in COVID‐19
  Fingolimod                                   Sphingosine‐1‐phosphate receptor regulator                                                                                                            1                         Animal models of neurodegenerative disease
  Intravenous immunoglobulin                   Block FcR activation                                                                                                                                  8                         Animal models of arthritis, nephrotoxic nephritis and idiopathic thrombocytopenic purpura
  Kineret (Anakinra)                           Interleukin‐1(IL‐1) receptor antagonist                                                                                                               5                         FDA approved to treat rheumatoid arthritis and neonatal‐onset multisystem inflammatory disease
  Naproxen                                     Inhibitor of both COX‐2 of influenza A virus NP                                                                                                       1                         *In vitro* data
  Pirfenidone                                  Inhibits IL‐1β and IL‐4                                                                                                                               1                         FDA approved for idiopathic pulmonary fibrosis
  Ruxolitinib                                  JAK 1 and JAK 2 inhibitor                                                                                                                             6                         FDA approved for the treatment of myelofibrosis, polycythemia vera, and graft‐versus‐host disease
  Sarilumab                                    Recombinant human anti‐IL6R monoclonal Ab                                                                                                             8                         Humanized animal model of acute inflammation
  Siltuximab                                   Anti‐IL‐6 chimeric monoclonal antibody                                                                                                                3                         FDA approved for idiopathic multicentric Castleman\'s disease
  Stem cells therapy                           Anti‐inflammatory and immune regulatory functions -- induction of immune tolerance in autoimmune T cells and restore immune balance and homeostasis   20                        Animal models of influenza virus infection
  Steroids, methylprednisolone                 Inhibits the gene expression of multiple cytokines (e.g. IL‐1, IL‐2, IL‐6, IFN‐gamma and TNF‐alpha)                                                   13                        Potent anti‐inflammatory activity; possible negative impact on viral load
  Thalidomide                                  Reduces TNFα                                                                                                                                          2                         *In vitro* data
  Tocilizumab                                  Recombinant humanized anti‐IL‐6R monoclonal Ab                                                                                                        22                        Recombinant humanized anti‐IL‐6R monoclonal Ab
  Vitamin C                                    Antioxidant properties                                                                                                                                13                        Animal models of asthma
  Others                                                                                                                                                                                                                       
  Carrimycin                                   Macrolide antibiotic                                                                                                                                  1                         *In vitro* data
  Heparin                                      Anticoagulant                                                                                                                                         5                         FDA approved for prophylaxis or treatment of thrombosis
  Losartan                                     Angiotensin II receptor blocker                                                                                                                       8                         Animal models of SARS‐CoV

ACE, angiotensin‐converting enzyme; COX‐2, cyclooxygenase‐2; HCV, hepatitis C virus; IL‐6R, interleukin‐6 (IL‐6) receptor; MERS‐CoV, Middle East respiratory syndrome coronavirus; SARS‐CoV, severe acute respiratory syndrome coronavirus; TMPRSS2, transmembrane serine protease 2; TNFα, tumor necrosis factor α; VEGF, vascular endothelial growth factor.

The research of the clinical trials has been done using the following keywords: COVID, COVID‐19, SARS‐CoV‐2 or novel coronavirus, together with the name of each drug (<https://clinicaltrials.gov>. Accessed on April, 20 2020)\*. For testing in COVID‐19.
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Most trials allow participation of transplant recipients, but they are not designed to address the specific questions the transplant physicians are facing. While post hoc analyses may allow to define characteristic responses in transplant patients, ad hoc trials are urgently needed in transplant patients. Should immunosuppression be reduced to unleash the antiviral response or maintained to prevent uncontrolled inflammatory response? Should certain immunosuppressive drugs be maintained based on their supposed antiviral effects? Is the antibody response different in transplant patients? These are only some of the questions warranting crucial answers.

This crisis has shown how vulnerable we are and foreshadows that our community and humanity at large will face more of these emergencies in the future. However, the great collaborative effort of the scientific community and the highly translational approach of the clinical studies are a true demonstration of National Institutes of Health (NIH)' mission, seeking "fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability" \[[4](#tri13626-bib-0004){ref-type="ref"}\]. This experience proves that scientists in numerous fields can fruitfully interact and leverage their own expertise to make the world healthier and a safer place. The transplant community should have a leading role in this effort to understand COVID‐19 pathophysiology in the unique population of organ recipients on chronic immunosuppression.
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